Literature DB >> 1385530

Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood.

T Miyawaki1, T Uehara, R Nibu, T Tsuji, A Yachie, S Yonehara, N Taniguchi.   

Abstract

The Fas Ag is a newly defined cell-surface molecule that may mediate apoptosis. The antibody against Fas Ag can induce the apoptotic cell death in cell lines expressing this Ag. PBL subpopulations at various ages were here examined for Fas expression by two-or three-color flow-cytometric analyses using anti-Fas mAb. It was found that Fas Ag was appreciably detected on a proportion of T and B cells, whereas its expression was absent for NK cells. For CD4+ and CD8+ T cells, Fas Ag was expressed preferentially on CD45RO+ (memory or previously activated) populations, but not on CD45RO- naive ones. TCR-gamma/delta+ T cells, especially their CD45RO+ subsets, also expressed Fas Ag. Expectably, neonatal T cell subpopulations, most of which had the naive (CD45RO-) phenotype, expressed little Fas Ag. Fas-expressing B cells dominated in surface(s) IgD- populations, but neonatal B cells as well as adult sIgD+ B cells had little Fas Ag. The Fas Ag was inducible after in vitro mitogenic stimulation of naive T and B cells from neonatal blood. These observations suggested that expression of Fas Ag on T and B cells in the peripheral blood might reflect their in vivo Ag-activated status. In contrast to Fas-expressing cultured cell lines, however, viability of in vitro stimulated T and B cells as well as freshly isolated CD45RO+ T cells was not significantly changed after the treatment with anti-Fas mAb, indicating that additional cellular conditions to Fas expression might be required for anti-Fas-induced cell death.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1385530

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  102 in total

Review 1.  Death and destruction of activated T lymphocytes.

Authors:  I N Crispe
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

Review 2.  Treatment of an autoimmune disease with "classical" T cell veto: a proposal.

Authors:  U D Staerz; Y Qi
Journal:  J Clin Immunol       Date:  1999-07       Impact factor: 8.317

Review 3.  Molecular steps of cell suicide: an insight into immune senescence.

Authors:  S Gupta
Journal:  J Clin Immunol       Date:  2000-07       Impact factor: 8.317

Review 4.  Death receptor signaling and autoimmunity.

Authors:  Richard M Siegel; Jagan Muppidi; Margaret Roberts; Melissa Porter; Zhengqi Wu
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

Review 5.  The CD8+ T Cell Noncytotoxic Antiviral Responses.

Authors:  Maelig G Morvan; Fernando C Teque; Christopher P Locher; Jay A Levy
Journal:  Microbiol Mol Biol Rev       Date:  2021-05-12       Impact factor: 11.056

6.  Effects of three consecutive days exercise on lymphocyte DNA damage in young men.

Authors:  Yuko Tanimura; Kazuhiro Shimizu; Kai Tanabe; Ichiro Kono; Ryuichi Ajisaka
Journal:  Eur J Appl Physiol       Date:  2010-05-16       Impact factor: 3.078

7.  Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis.

Authors:  Gianpietro Dotti; Barbara Savoldo; Martin Pule; Karin C Straathof; Ettore Biagi; Eric Yvon; Stephane Vigouroux; Malcolm K Brenner; Cliona M Rooney
Journal:  Blood       Date:  2005-02-15       Impact factor: 22.113

8.  Influence of the lpr environment on the lymph node cell phenotypes in C57BL/6 nubg and nulpr chimeras.

Authors:  F Tiberghien; R Ceredig; F Loor
Journal:  Immunology       Date:  1994-12       Impact factor: 7.397

9.  Insufficient expression of Fas antigen on helper T cells in Behçet's disease.

Authors:  S Nakamura; M Sugita; H Matoba; S Tanaka; F Isoda; S Ohno
Journal:  Br J Ophthalmol       Date:  1996-02       Impact factor: 4.638

10.  Functional and phenotypic changes in circulating lymphocytes from hospitalized zambian children with measles.

Authors:  Judith J Ryon; William J Moss; Mwaka Monze; Diane E Griffin
Journal:  Clin Diagn Lab Immunol       Date:  2002-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.